Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

NCT04225312 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

300

Enrollment

OTHER

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

DRUG: Personalized extended interval dosing of natalizumab
DRUG: Standard interval dosing

Sponsor

Amsterdam UMC, location VUmc

Collaborators

[object Object]
[object Object]
[object Object]